FEATURED NEWS
- May 28, 2026Education
InternSync Aims to Rebuild Early-Career Access for High School Students and Small Businesses
InternSync is building a high-school-first marketplace that helps students access real-world internships, competitions, and other remote-friendly roles while giving small and mid-sized businesses a structured way to find vetted early talent. Photo courtesy of Shourya Kancharla After seeing how high school classmates with computer science parents and finance connections could tap into internships through family networks, while others sent cold emails and LinkedIn messages that went nowhere, founder Shourya Kancharla set out to create the kind of access platform that did not exist when he started searching for work experience. InternSync’s swipe-style discovery model and common application are designed so that students can express interest quickly, while businesses review standardized profiles instead of uneven resumes. InternSync says the app currently lists more than 7,500 internships, competitions, and other remote-friendly roles that high school students are eligible to pursue. Small and mid-sized businesses use the platform to reach youth applicants through a standardized intake format that presents comparable candidate profiles rather than uneven resumes. InternSync’s early data from its MVP period shows that more than 2,000 students have used the platform, and over 50 small and mid-sized businesses have partnered with the company to post roles over time. The company notes that many of these businesses return to list additional openings, signaling that structured intake, comparable candidate information, and youth-focused outreach help them fill roles related to automation support, data tasks, website updates, and social media. A key feature of InternSync is its blind common application, which is designed to match students with opportunities that align with their skills, interests, and strengths. Through a standardized set of questions, the platform aims to develop a deeper understanding of each student’s capabilities beyond a traditional resume while reducing bias in the application process. InternSync says this approach helps guide students toward roles that are a stronger fit for their backgrounds and potential, while giving businesses a more consistent and comparable way to evaluate candidates across opportunities. “High school students struggle to find real opportunities long before they ever get compared with older candidates, and small businesses struggle just as much to find vetted young talent they can actually work with,” said Shourya Kancharla, founder of InternSync. “InternSync exists so a student who doesn’t have family connections can still be seen by real businesses, and so those businesses can discover early talent through a format that is structured, comparable, and built for them.” InternSync is currently raising a pre-seed round to expand the platform and grow its network of student users and business partners. The company’s longer-term plan includes extending the marketplace to serve college students while keeping its initial focus on high school users and small to mid-sized businesses seeking early-career talent. About InternSync InternSync is building a high-school-first marketplace that connects students with internships, competitions, and other remote-friendly opportunities through a swipe-based discovery experience and a standardized common application. The company’s mission is to make early-career access less dependent on personal networks and to give small and mid-sized businesses a scalable way to discover and develop young talent.
- May 28, 2026Technology
Buble Expands AI Creative Workflow Capabilities for Marketing and Content Teams
As marketing teams face increasing pressure to produce high volumes of visual content across multiple digital channels, AI-powered creative platforms are rapidly evolving from experimental tools into essential workflow infrastructure. Buble, an AI creative workspace available at https://buble.ai/ , is positioning itself at the center of this shift by helping teams streamline the process from idea generation to visual execution. Modern marketing campaigns demand faster decision-making, continuous testing, and multi-format asset production across social media, advertising, product launches, and branded content. While traditional creative workflows often require lengthy production timelines before concepts can be evaluated, AI-assisted tools are enabling businesses to generate early-stage visuals and motion concepts significantly faster. Buble’s platform is designed to support this growing need for rapid creative iteration by combining image generation, video creation, and model-based experimentation within a unified workspace. Rather than focusing solely on single-use AI outputs, the platform aims to help teams move efficiently from prompts and drafts to reviewable creative concepts that can guide production decisions. Video production remains one of the largest challenges for marketing and content teams due to the time and resources typically required during concept development. Through its AI video workflow at https://buble.ai/ai-video-generator , Buble allows users to create and test short-form visual concepts before committing to more resource-intensive production stages. The platform also supports image-based creative development through its AI image generation tools at https://buble.ai/ai-image-generator . Marketing teams can use these workflows to explore campaign visuals, product imagery, thumbnails, blog graphics, and creative variations during the planning phase of a campaign. Industry observers note that one of the key advantages of AI-assisted creative workflows is the ability to evaluate multiple visual directions earlier in the process. Faster concept validation can help reduce production waste, improve campaign planning efficiency, and support quicker collaboration between marketing, design, and product teams. Buble also provides access to multiple AI model options through dedicated environments such as https://buble.ai/veo-3-1 and https://buble.ai/nano-banana-2 . Different models may be better suited for cinematic visuals, stylized outputs, reference editing, or image detail, allowing users to adapt workflows based on project requirements without switching between disconnected systems. The broader market trend reflects increasing demand for AI tools that function as integrated production layers rather than standalone novelty generators. Businesses ranging from startups and agencies to product teams and content studios are increasingly exploring AI-assisted workflows to support brainstorming, asset generation, and creative testing at earlier stages of production. While AI-generated outputs continue to require human review for quality control, brand alignment, compliance, and refinement, many organizations are beginning to treat AI as a strategic workflow enhancement rather than a replacement for creative expertise. As digital content production continues to accelerate across industries, platforms focused on faster visual experimentation and collaborative creative workflows are expected to play an increasingly important role in modern marketing operations.
- May 28, 2026Lifestyle
RxPepsDirect Offers Compounded GLP-1 Weight Loss Medications Starting at $25 Through Direct-to-Pharmacy Model
RxPepsDirect, a Colorado-based telehealth service prescribing compounded peptide therapies, today highlighted its direct-to-pharmacy pricing model for compounded semaglutide and tirzepatide, the same active molecules found in branded GLP-1 medications Ozempic, Wegovy, Mounjaro, and Zepbound. Patients can begin treatment with a starter vial of compounded Semaglutide/B12 for $25 or compounded Tirzepatide/B12 for $45, plus a one-time $39 medical visit fee, with the medication cost billed separately by the pharmacy at wholesale. Branded GLP-1 medications typically cost between $1,000 and $1,200 per month, cash-pay before insurance. The RxPepsDirect model separates the prescribing relationship from the pharmacy transaction: RxPepsDirect providers conduct the telehealth visit and write the prescription, and Optimal Balance Pharmacy, a Texas-licensed 503A compounding pharmacy, fills the prescription and bills the patient directly at pharmacy wholesale pricing. No clinic markup is added to the medication cost. "Most telehealth GLP-1 services bundle the medication into a monthly subscription that hides the markup," said Marcus Hansen, CEO at RxPepsDirect. "We made a different choice. The medical visit is $39 once. The pharmacy bills patients at its wholesale rate. Patients can see every vial in the dose ladder priced publicly before they ever start treatment." How the Direct-to-Pharmacy Model Works Patients begin with a telehealth visit through RxPepsDirect, during which a licensed nurse practitioner or physician assistant reviews medical history, screens for contraindications, and writes a patient-specific prescription under Section 503A of the Federal Food, Drug, and Cosmetic Act. Optimal Balance Pharmacy compounds the medication and ships it directly to the patient. Shipping is billed by the pharmacy and is separate from the medication cost. Every batch dispensed is independently tested by Eagle Analytical Services, an FDA-registered laboratory in Houston, Texas, for sterility and bacterial endotoxin per USP <85>. Certificates of Analysis are published on each product page. Pricing Across the Titration Ladder The standard six-month titration protocol for compounded Semaglutide/B12 begins at $25 for the 1.2mg starter vial in Month 1 and climbs to $108.64 for the 11.2mg maintenance vial in Month 6. Compounded Tirzepatide/B12 begins at $45 for the 12mg starter vial and reaches $247.50 for the 66mg maintenance vial. All vial prices are published on the public product pages, allowing patients to plan the full cost trajectory before beginning treatment. The pivotal STEP-1 trial reported approximately 14.9 percent mean body weight loss on semaglutide over 68 weeks. The SURMOUNT-1 trial reported 15 to 22 percent mean body weight loss on tirzepatide over 72 weeks. Compounded versions use the same active molecules studied in those trials, prepared by a licensed compounding pharmacy under a patient-specific prescription. Regulatory Pathway and Safety Compounded semaglutide and tirzepatide are dispensed under the 503A patient-specific pathway, which was unaffected by the March 2025 end of the FDA enforcement-discretion period for 503B outsourcing facilities. Each prescription is written for an identified individual patient with documented medical need. Compounded medications are not FDA-approved drug products and are not the same as branded Ozempic, Wegovy, Mounjaro, or Zepbound. GLP-1 medications are contraindicated for patients with a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, active pancreatitis, or severe gastroparesis. The RxPepsDirect intake includes screening for these conditions, and continued refills require verification of active medical care. Availability RxPepsDirect currently serves patients in 32 US states through licensed nurse practitioners and physician assistants. Eligibility is confirmed during the intake process. About RxPepsDirect RxPepsDirect is a Denver, Colorado-based telehealth platform connecting patients with licensed providers for compounded peptide therapies, including GLP-1 weight loss medications, muscle growth and recovery peptides, longevity protocols, and other formularies. Prescriptions are dispensed by Optimal Balance Pharmacy, a Texas-licensed 503A compounding pharmacy, with independent batch testing by Eagle Analytical Services. The platform operates on a direct-to-pharmacy model with no clinic markup on medication and no subscription requirement. More information is available at https://www.rxpepsdirect.com . Learn More Compounded Semaglutide/B12 pricing and protocol: https://www.rxpepsdirect.com/peptides/weight-loss/semaglutide-b12 Compounded Tirzepatide/B12 pricing and protocol: https://www.rxpepsdirect.com/peptides/weight-loss/tirzepatide-b12 2026 compounded tirzepatide telehealth comparison: https://www.rxpepsdirect.com/learn/best-compounded-tirzepatide-telehealth Compounded semaglutide and tirzepatide are not FDA-approved drug products and are not the same as branded Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications are prepared by licensed pharmacies under patient-specific prescriptions. Individual results may vary. This release is not a substitute for professional medical advice. Optimal Balance Pharmacy is licensed to ship compounded medications to patients in 32 US states and DC; telehealth provider licensing varies by state.
- May 28, 2026Technology
DeRiddle.Life Founder Suryatapa Roy Launches Human-AI Collaboration Platform Designed to Help Individuals and Organisations Evolve With and Alongside Modern Technology
Suryatapa Roy, data scientist, AI architect, and doctoral researcher in Brain-Machine Interfaces, has launched DeRiddle.Life, a human-AI collaboration platform building a suite of tools designed to help individuals and organisations navigate the cognitive, behavioural, and operational dimensions of AI adoption. The platform's mission is to enable humans to evolve with technology, and its vision is to serve users as a personal compass for balanced living. DeRiddle.Life does not fit neatly into any single category. It has components of a learning platform, a productivity tool, a personalised AI assistant, a self-improvement platform, and a marketplace. Roy describes it as none of these things individually, but all of them coming together in bespoke ways. What unifies the platform is a research-led conviction: that the path to sustainable AI adoption is not teaching everyone to prompt AI tools more effectively. It is understanding and supporting the complex effect that AI adoption has on human cognition, personal fulfilment, and the way people find meaning in their work and lives. The Platform: Two Suites, One Mission DeRiddle.Life is currently developing two suites of tools. The personal suite covers three applications: In My Tune for self-development, Jekeu Books for self-analytics, and Elemental Dynamics for self-discovery. The business suite covers Edge Up for AI adoption, Skill Up for employee training, and Scale Up for research and development. Research on human behaviour, cognition, and motivation is at the core of every tool in both suites. The platform's approach is explicitly adaptive: the use of technology is a subjective experience, and DeRiddle.Life is designed to personalise technology solutions for individual users rather than apply a uniform framework. The advisory network Roy is building connects human experts, products, and services to develop the best adaptation strategy for each context. The Research Foundation Behind DeRiddle.Life Roy brings an unusually deep technical and human-centred foundation to this work. She holds a master's degree in human-centred machine learning and is currently conducting doctoral research in Brain-Machine Interfaces. For the past seven years, she has worked as a Data Scientist and AI Architect at a leading technology startup in Calgary, developing practical experience at the intersection of human-centred computing and artificial intelligence. That background informs a perspective she has been developing publicly through her writing on Medium and through her speaker series, How to Succeed at Life, hosted on Meetup, where she examines questions about fear, leadership, collaboration, and success, and explores what AI adoption means for human evolution more broadly. In one recent piece, she examines the evolutionary function of fear and stress responses and their relationship to action and intelligence. In another, she explores the relationship between chaos, silence, and the learning of meaning, arguing that the pursuit of knowledge without self-reflection and purpose is insufficient, and that AI systems learning to emulate human meaning-making without understanding it present a risk that warrants serious structural attention. Her conclusion is not alarmist. It is architectural. "Incorporating intelligent systems to enable humans to make better and faster decisions is definitely the intention behind this science," she has written. "But we still have very limited understanding of the learning abilities of each individual. We need a lot more research in this area to truly realise the promise of a collaboration between human and artificial intelligence." DeRiddle.Life is that research, made into a platform. Why Human-AI Collaboration Requires More Than Better Prompting Roy's central argument, and the founding premise of DeRiddle.Life, is that the dominant conversation about AI adoption is focused on the wrong problem. Organisations are asking how to get their people to use AI tools more effectively. The more important question, in Roy's view, is what AI adoption is doing to the people using those tools, and how organisations can support human cognition, satisfaction, and fulfilment through a more sustainable transition that is already deeply affecting both. The six tools DeRiddle.Life is developing, across personal and business suites, are each designed to address a different dimension of that question. Self-development, self-analytics, self-discovery, AI adoption support, employee training, and research and development are not separate product lines. They are interconnected interventions in the same underlying challenge: enabling humans to evolve alongside technology in ways that are sustainable for the individual and the organisation. About DeRiddle.Life DeRiddle.Life i s a human-AI collaboration platform founded by Suryatapa Roy, developing personalised tools for individual and organisational AI adoption across personal development, employee training, and enterprise research. Its mission is to enable humans to evolve with technology, and its vision is to serve users as a personal compass for balanced living. Current tools in development include In My Tune, Jekeu Books, Elemental Dynamics, Edge Up, Skill Up, and Scale Up. Beyond a suite of AI-adaptive tools, Roy's ambition for DeRiddle.Life is to establish it as a framework for sustainable human and AI collaboration. Deeply committed to an individual-first approach to productivity and growth, the platform's mission is to continue enabling humans to evolve with technology. For more information and to be part of the conversation, visit deriddle.life , watch at youtube.com/@DeRiddle_Life , or join the community at meetup.com/health-and-wellness-society .
- May 28, 2026Business
TravelGrowth AI Introduces a New Growth System Designed to Help Businesses Turn Visibility Into Revenue
Co-founded by Brigitte Charles, CEO and CFO, and Icare Hydn Duplessy, Chief Visionary Officer, TravelGrowth AI was built around a problem the founders identify consistently across the businesses they work with: companies are investing heavily into marketing, software, advertising, content, and customer acquisition, yet many still struggle with inconsistent sales, weak follow-up, fragmented customer journeys, poor conversion tracking, and rising customer acquisition costs. The result, in the company's assessment, is that businesses generate traffic, leads, attention, and customer interest without fully converting those opportunities into predictable revenue growth. Many businesses today have visibility, traffic, and marketing activity, but their systems are not coordinated. Customer journeys become fragmented, opportunities are detected too late, follow-up happens slowly, and results do not improve over time. TravelGrowth AI states that it was created to solve that problem by helping businesses connect visibility, customer demand, customer journeys, relationships, and execution into one coordinated growth system designed to produce measurable business results. The company's operating philosophy is built around a framework it describes as: Signals. Decisions. Outcomes. Rather than operating like a traditional marketing agency, TravelGrowth AI focuses on helping businesses find opportunities earlier, improve customer journeys, strengthen business relationships, coordinate execution, automate follow-up, and create warmer sales conversations that lead to stronger long-term growth. "At many companies, the issue is not effort," said Brigitte Charles, CEO and CFO of TravelGrowth AI. "The issue is that visibility, trust, customer relationships, follow-up, and execution are often disconnected. Businesses are generating attention but still struggling to turn that attention into measurable revenue growth. We built TravelGrowth AI to help companies connect those layers into one coordinated system." TravelGrowth AI combines visibility systems, automation, customer journey coordination, operational execution, conversion optimisation, business intelligence, and relationship-driven growth systems into one unified framework designed to help businesses generate more qualified opportunities, improve conversions, strengthen trust, and create more predictable growth. The company is also expanding its intelligence ecosystem through AI-driven systems and operational agents designed to help businesses respond faster, automate repetitive workflows, improve decision-making, coordinate customer interactions, and reduce the fragmentation that often slows growth. TravelGrowth AI's position is that AI agents and coordinated intelligence systems will become an increasingly important part of how businesses manage visibility, customer relationships, operations, and revenue growth over the coming years. SoulScan and the RAAS Model One of the company's core systems is SoulScan , a relationship intelligence and Revenue Architecture as a Service system designed to help businesses create warmer sales conversations, stronger buyer relationships, and higher-quality business opportunities through visibility, trust, strategic relationship coordination, and stronger business positioning. Instead of relying only on advertising or cold outreach, SoulScan focuses on helping businesses improve credibility, strengthen buyer conversations, and create better business opportunities through curated business environments and coordinated relationship systems. Partnership With Xraised As part of its expansion, TravelGrowth AI has entered into a formal strategic partnership agreement with Xraised, the UK-based media and interview platform operated by DGL Media Solutions Ltd. Together, the companies support a panel-based business visibility model that brings together one host, one expert, and three to five curated participants for strategic business conversations designed to create stronger visibility, trust, relationships, and long-term business opportunities. Under the agreement, TravelGrowth AI operates as a strategic partner with operational autonomy in sourcing, structuring, and coordinating these curated business conversations using its proprietary relationship intelligence and business growth systems. "This is not about selling interviews or running PR campaigns," said Icare Hydn Duplessy, Chief Visionary Officer of TravelGrowth AI. "It is about helping businesses create stronger trust, better visibility, warmer conversations, and more measurable business growth over time." Once recorded, these business conversations can be distributed across media platforms, search engines, social channels, and digital ecosystems, helping businesses create long-term content assets, stronger online visibility, increased credibility, and additional business opportunities. TravelGrowth AI has also participated in published business conversations distributed across digital media platforms, including the Xraised Spotify episode AI Driven Travel Growth, where the discussion focused on AI-driven travel growth, customer journeys, automation, visibility, and measurable business growth. The episode is available here . StreamSell24 The broader TravelGrowth AI ecosystem also includes StreamSell24, a live-selling and audience engagement platform focused on helping companies turn real-time audience attention and engagement into measurable sales opportunities. TravelGrowth AI currently works with companies across travel, hospitality, tourism, experiences, marketplaces, service businesses, and other demand-driven industries where, in the company's view, visibility alone is no longer sufficient to create predictable growth. About TravelGrowth AI TravelGrowth AI is a business growth and execution ecosystem designed to help companies connect visibility, customer demand, relationships, and execution into measurable business growth. The company focuses on helping businesses improve visibility, strengthen trust, create warmer customer conversations, coordinate execution, improve conversions, and turn fragmented demand into stronger long-term business opportunities. Its ecosystem includes SoulScan, a relationship intelligence and Revenue Architecture as a Service system, and StreamSell24, a live-selling and audience engagement platform. For more information visit travelgrowth.ai.
- May 28, 2026Health
Secure Medical Inc. Unveils PrescriptionHub.com: The Evolution of TelehealthCash Into a Full-Scale Digital Healthcare Ecosystem
Secure Medical Inc. today announced the continued expansion and official rollout of PrescriptionHub.com , the company’s most ambitious healthcare technology launch to date. Built from the infrastructure, data flow, and operational intelligence originally developed through TelehealthCash, PrescriptionHub represents the next generation of customizable telemedicine, pharmacy, and healthcare commerce solutions. What started as TelehealthCash helping organizations streamline telehealth lead generation, patient acquisition, and operational workflows has now evolved into a fully integrated healthcare ecosystem designed for doctors, pharmacies, healthcare partners, and entrepreneurs looking to launch scalable digital healthcare businesses. PrescriptionHub gives healthcare providers and partners the ability to launch their own white-labeled telehealth platforms, manage patient consultations, generate e-prescriptions, fulfill medications, and operate online pharmacy storefronts through one centralized system. ( prescriptionhub.com ) Industry insiders are already describing the platform as “what happens when a direct-to-consumer healthcare company meets a modern telemedicine network and prescription savings marketplace.” In simple terms, PrescriptionHub combines the convenience and branding capabilities of companies like Hims and eDrugstore , the virtual care infrastructure of Teladoc Health and OurDoctor , while incorporating medication flexibility and pharmacy connectivity similar to GoodRx and BidRx into one seamless platform. PrescriptionHub allows providers to: Launch branded telehealth websites without complex development Offer secure video, audio, and asynchronous consultations Generate instant e-prescriptions Connect patients directly with pharmacy fulfillment Offer OTC and prescription medication storefronts Manage patient flow, consultations, and reporting in one dashboard Scale operations remotely from virtually anywhere in the world The platform made its public debut during the recent ATA Nexus 2026, where the response from healthcare professionals, pharmacies, and strategic partners exceeded expectations. According to Secure Medical Inc., signups, demo requests, and white-label partnership inquiries surged immediately following the event, signaling what many in the healthcare technology space already recognize: the migration away from traditional brick-and-mortar healthcare models is accelerating rapidly. Doctors and healthcare operators are increasingly seeking systems that allow them to consult, prescribe, fulfill, and manage patient relationships digitally while maintaining compliance, convenience, and operational scalability. PrescriptionHub was engineered specifically for that future. Kyle Rao of Secure Medical Inc. described PrescriptionHub as “the Mona Lisa of my accomplishments in the healthcare industry,” adding that he believes the platform will become “a true game changer for the future of digital healthcare.” “The healthcare industry is evolving beyond physical walls,” says Kyle Rao. “Providers want the freedom to practice remotely, pharmacies want scalable digital fulfillment tools, and healthcare entrepreneurs want turnkey infrastructure without spending years building technology from scratch. PrescriptionHub brings all of those pieces together.” The company says one of the platform’s strongest differentiators is customization. Unlike many rigid telehealth systems currently on the market, PrescriptionHub allows doctors, pharmacies, and partners to create tailored healthcare experiences under their own branding while leveraging Secure Medical’s backend infrastructure and operational expertise. The system also addresses a growing demand for hybrid healthcare commerce, where consultation, prescription management, pharmacy fulfillment, patient communication, and digital storefront capabilities all coexist inside one ecosystem rather than across disconnected vendors and software stacks. Healthcare operators attending ATA Nexus 2026 noted the increasing industry demand for remote-first medical operations, particularly as patients continue prioritizing convenience, privacy, affordability, and accessibility in healthcare delivery. From virtual consultations to medication delivery and pharmacy integrations, PrescriptionHub aims to centralize the modern patient journey into a single digital experience. Secure Medical Inc. believes this launch marks a major turning point not only for the company, but for the telehealth industry as a whole. “The future has arrived,” the company added. “Healthcare is no longer tied to a waiting room. It’s connected, customizable, scalable, and accessible from anywhere.” Healthcare providers, pharmacies, affiliates, entrepreneurs, and strategic partners interested in exploring the platform can request a free demo or begin onboarding directly through PrescriptionHub.com .
- May 28, 2026Medicine & Pharmaceuticals
Ace Therapeutics Expands Comprehensive Heart Disease Research and Drug Development Solutions
Ace Therapeutics, a specialized contract research organization focusing on preclinical cardiovascular research , has unveiled its full-spectrum heart disease research and drug development services to support global academic institutions and biopharmaceutical enterprises in advancing cardiovascular therapeutic innovation. Heart disease remains one of the top global causes of mortality, accounting for 32% of all deaths worldwide. Pathological triggers including unhealthy lifestyles, genetic mutations, endothelial dysfunction, hyperlipidemia, and hypertension significantly elevate cardiovascular disease risks. Classified broadly into congenital and acquired heart diseases, conditions such as coronary atherosclerotic heart disease stand out as major research priorities in modern medical science. Leveraging decades of accumulated expertise in cardiology, Ace Therapeutics delivers integrated solutions covering basic pathological research, biomarker development, and novel drug discovery. A core highlight of Ace Therapeutics' services lies in its professional atherosclerosis drug discovery services , which cover the entire research workflow from pathogenesis exploration and regulated cell death mechanism analysis to preclinical candidate validation. Supported by in-depth studies on fundamental regulated cell death mechanisms underlying heart disease, including apoptosis, ferroptosis, pyroptosis and autophagy-dependent cell death, the service streamlines target identification, compound screening and efficacy assessment for atherosclerosis-related drug candidates. To facilitate reliable in vivo research and accelerate preclinical trials, Ace Therapeutics also provides tailored custom atherosclerosis animal models for researchers. These customized models are well-constructed to mimic the pathological progression of atherosclerosis, enabling accurate evaluation of drug efficacy and safety. Beyond atherosclerosis-focused services, Ace Therapeutics builds animal models and conducts research for a wide range of cardiovascular conditions, including angina pectoris, myocardial infarction, arrhythmia, heart failure, cardiomyopathy, and infectious heart diseases. Ace Therapeutics offers one-stop outsourcing services encompassing animal model construction, pathogenesis mechanism research and novel drug development. By combining professional technical platforms and profound industry knowledge, Ace Therapeutics continues to empower clients to break through bottlenecks in heart disease research and drug development, driving the creation of more effective cardiovascular treatment options. About Ace Therapeutics Ace Therapeutics is a leading provider of preclinical contract research services, dedicated to supporting pharmaceutical companies, universities, and research institutions worldwide. The company’s expertise spans custom animal model development, efficacy testing, and PK/PD evaluation—all backed by state-of-the-art facilities and a team of experienced researchers. Ace Therapeutics' mission is to drive innovation in preclinical development by delivering reliable, personalized solutions that advance scientific discovery and improve global health.
- May 28, 2026Medicine & Pharmaceuticals
Amerigo Scientific Rolls Out Comprehensive Portfolio of High-Performance Chiral Columns for Multi-Industry Enantiomer Separation
Amerigo Scientific has launched an extensive portfolio of premium chiral chromatography columns, catering to analytical testing, small-scale laboratory separation, and commercial enantiomer separation across pharmaceuticals, fine chemicals, food science, and environmental analysis sectors. Chiral compounds are prevalent in nature and synthetic manufacturing, with key biological molecules including amino acids, sugars, and nucleic acids possessing chiral properties. Many pharmaceutical compounds also exist as enantiomers, mirror-image stereoisomers that differ greatly in biological interaction, safety, and therapeutic efficacy. This makes enantiomeric purity verification and individual enantiomer quantification indispensable throughout drug discovery and development workflows. Chiral chromatography has emerged as the core analytical technique for separating chiral mixtures, relying on enantiomeric selectivity delivered by chiral stationary phases, chiral mobile phases or added chiral selectors. Among mainstream technologies, high performance liquid chromatography (HPLC) equipped with chiral stationary phases stands out as the most widely adopted, accurate and efficient solution. Amerigo Scientific's chiral column portfolio features exceptional durability, long service life, and outstanding racemate resolution, while enabling fast, streamlined method development for laboratory and industrial applications. The product range covers multiple categories to meet diverse separation demands. Its chiral HPLC columns include conventional polysaccharide-based models, solvent-resistant immobilized variants, and protein stationary phase-based columns. Specialty offerings encompass HPLC columns with crown ether, anion exchange, and ligand exchange stationary phases. Beyond HPLC, Amerigo Scientific provides chiral supercritical fluid chromatography (SFC) columns that use carbon dioxide supercritical fluid as the mobile phase. These SFC columns deliver high-resolution separation for complex chiral mixtures, coupled with low back pressure and minimal solvent consumption, supporting sustainable and efficient analytical operations. Amerigo Scientific's chiral stationary phase platforms span Pirkle-type, ligand-exchange, molecularly-imprinted designs, alongside phases based on polysaccharides, macrocyclic antibiotics, proteins, cyclodextrins, crown ethers, cyclofructins, and synthetic polymers. All columns are engineered to facilitate preferential interaction with one enantiomer in a mixture, creating differential migration velocities to achieve effective elution and separation. As a critical supplier of chromatographic solutions, Amerigo Scientific continues to expand its chiral column specifications and technical capabilities, aiming to support researchers and manufacturers in rigorous chiral compound analysis, purity control, and large-scale enantiomer production globally. About Amerigo Scientific Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation from all companies and institutions in the area of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers’ questions or concerns and are always ready to provide individualized customer service of high standards.
- May 28, 2026Technology
Eata 3DPrint Expands Advanced Materials and Custom Manufacturing Capabilities for Industrial Applications
Eata 3DPrint, a provider of advanced additive manufacturing solutions, today announced the expansion of its portfolio of high-performance 3D printing materials and precision custom manufacturing services for industrial and research applications. The expanded offering is designed to help companies accelerate product development, reduce production lead times, and improve manufacturing flexibility through digital production technologies. Advanced Materials Designed for Precision Manufacturing Eata 3DPrint offers a broad range of 3D printing materials developed for compatibility with major additive manufacturing platforms, including metal powders, thermoplastic filaments, photopolymer resins, bioinks, industrial ceramics, silicon-based materials, and bio-derived alternatives. The materials are engineered to deliver reliable print performance, dimensional consistency, and application-specific mechanical properties across aerospace, automotive, medical, industrial, and research environments. The company’s portfolio includes high-density metal powders for functional industrial components, engineering-grade ABS and reinforced nylon filaments, and high-precision SLA resins designed for fine-detail printing applications such as dental models, prototyping, and consumer products. “Our focus is on helping customers achieve more reliable and repeatable printing results,” said a senior expert for Eata 3DPrint. “From industrial metal parts to highly detailed resin models, we develop materials that improve print stability, surface quality, and overall production efficiency.” Flexible Manufacturing Services for Research and Industry Alongside its material portfolio, Eata 3DPrint provides custom 3D print services that support projects ranging from early-stage prototyping to low-volume production. Using industrial SLA, DLP, SLS, and SLM systems, the company can produce both prototype and end-use parts for customers in engineering, manufacturing, and scientific research sectors. The company also works closely with clients on design optimization for additive manufacturing, helping improve structural performance, reduce unnecessary material usage, and shorten development cycles. By removing the need for expensive tooling in many applications, customers can move from design to production significantly faster than with conventional manufacturing methods. “Additive manufacturing gives companies greater flexibility in how they design and produce components,” said the senior manager at Eata 3DPrint. “We aim to simplify the process for customers by combining material expertise, engineering support, and production capabilities under one service platform.” In addition to rapid prototyping and low-volume production, Eata 3DPrint offers customized post-processing services, including polishing, anodizing, coating, and assembly. The company also manufactures custom tooling, fixtures, and gauges designed to improve operational efficiency in industrial production environments. “Our expanded capabilities are designed to help customers bring products to market faster while maintaining the quality and precision required for demanding applications,” the senior manager added. About Eata 3DPrint Eata 3DPrint specializes in advanced 3D printing materials and additive manufacturing services for industrial and research applications. The company provides customized solutions spanning rapid prototyping, low-volume production, material development, and precision component fabrication. By combining engineering expertise, advanced manufacturing technologies, and application-focused material science, Eata 3DPrint helps customers accelerate innovation and improve production efficiency across a wide range of industries.
- May 28, 2026Science
Creative Biolabs Launches Integrated Analytical Platform to Optimize Biomass and Biogas Fermentation
As global demand for renewable energy, sustainable bioprocessing, and industrial biotechnology continues to rise, Creative Biolabs has expanded its quantitative profiling solutions for biomass analysis , algae characterization, and biogas fermentation monitoring. The advanced analytical platform is designed to help researchers and biotechnology companies achieve accurate biomass characterization, optimize fermentation efficiency, and accelerate bioenergy development through high-quality quantitative data. Accurate quantitative characterization remains a major challenge in biomass utilization and industrial fermentation optimization due to the complexity and variability of biological materials. To address these analytical bottlenecks, Creative Biolabs provides integrated profiling workflows combining chromatography, mass spectrometry, and customized data analysis strategies. Key features of the platform include: • Quantitative profiling of biomass components, including carbohydrates, lipids, proteins, lignin, metabolites, and fermentation-related compounds • Algae multi-component quantitative analysis supporting biofuel, nutraceutical, and environmental biotechnology research • Biogas fermentation process-based quantitative profiling for anaerobic digestion monitoring and methane production optimization • High-sensitivity analytical workflows for complex biological and industrial samples • Flexible project customization for renewable energy, industrial biotechnology, microbial fermentation, and carbon utilization studies As biomass-derived resources and algae-based production systems continue to gain importance in sustainable manufacturing and clean energy innovation, researchers increasingly require reliable analytical solutions for feedstock evaluation, process monitoring, and quality assessment. "Scaling up bioenergy production has long been hindered by the unpredictable nature of biological feedstocks," said the Chief Scientist at Creative Biolabs. "Our expanded testing platform injects molecular-level clarity into the process, effectively removing the guesswork for refiners and biotechnologists striving toward a net-zero future." The solutions are suitable for applications including: • Biomass feedstock characterization • Anaerobic digestion and biogas research • Fermentation process optimization • Renewable bioenergy development • Algae metabolite analysis • Industrial microbial biotechnology • Environmental and carbon utilization research Frequently Asked Questions (FAQs) Q1: What specific challenges does Creative Biolabs’ profiling platform address? The platform overcomes the analytical limitations of complex biological matrices, allowing researchers to accurately quantify highly variable compounds in raw biomass, microalgae cultures, and active biogas fermenters without sample cross-interference. Q2: What analytical technologies are used in the profiling workflows? Creative Biolabs utilizes advanced analytical technologies including chromatography, mass spectrometry, and customized bioanalytical workflows to achieve sensitive and reliable quantitative analysis. Q3: Can the services be customized for specific industrial biotechnology projects? Yes. Creative Biolabs provides flexible, client-specific protocols tailored to unique sample types, target analytes, and volume requirements across the renewable energy and microbial fermentation sectors. Researchers and biotech companies interested in biomass characterization, algae profiling, or fermentation analytics can explore customized solutions at https://www.creative-biolabs.com/glycoprotein/biomass-components-quantitative-profiling-services.htm . About Creative Biolabs Creative Biolabs provides advanced analytical and customized research services for biomass characterization, algae component analysis, and biogas fermentation. With expertise in chromatography, mass spectrometry, and bioanalytical technologies, the company supports global partners in renewable bioenergy, industrial biotechnology, fermentation optimization, and sustainable bioprocess development.
- May 28, 2026Technology
StarFront Unveils Roadmap for Precision Agriculture at World Drone Conference, Showcasing “Air-Ground Integration” Vision
The 10th World Drone Congress and the 13th International Conference on Precision Agricultural Aviation, held in Shenzhen from May 21 to 23, featured more than 1,200 enterprises from 17 countries, over 10,000 drones, and more than 180,000 professional visitors, including over 13,000 international attendees. As one of the world’s most authoritative platforms in the field, the conference invited Yang Bing, Global President of MOVA Smart Agriculture (StarFront) to deliver a keynote address, where he shared the company’s technological breakthroughs and strategic vision, positioning StarFront as a rising leader in smart agriculture innovation. StarFront is a dedicated provider of intelligent agricultural equipment, committed to delivering environmentally friendly, efficient, and precise solutions for global modern farming through advanced robotics technology. Three Pillars: Era, Technology, Ecology Yang opened by addressing the fundamental challenges facing modern agriculture: labor shortages, low efficiency, and the urgent need for sustainable practices. “Agricultural automation is no longer an option but a necessity,” he said. “StarFront positions itself as the ‘guardian of the fields’ – a total solution provider for smart agriculture.” On the technology front, Yang detailed the company’s closed-loop system of “see, compute, act,” powered by multispectral imaging, AI-based data analytics, RTK centimeter-level positioning, and a dynamic liquid circulation system for spraying. The flagship M150 agricultural drone, launched last year, embodies these capabilities, enabling precise operations across complex terrains including mountains, plains, and hills. Speaking on ecosystem development, Yang stressed that stand-alone intelligent equipment cannot meet the demands of modern farming. StarFront has therefore built a “Space-Air-Ground” sensing network, where drones collect aerial data and ground sensors monitor soil and crop conditions, all fed into the StarFront cloud platform. This enables variable-rate fertilization and precision spraying, marking a shift from automation to data-driven precision agriculture. New Products: Farming Robot and Harvesting Robot The highlight of the speech was the first public disclosure of StarFront’s upcoming product lineup. Yang announced that the company will soon launch a farming robot and a harvesting robot, further expanding its smart machinery portfolio. The farming robot is designed for primary tillage operations such as land leveling, ridging, and rotary tilling. The harvesting robot, equipped with intelligent vision and a flexible robotic arm, can adapt to various fruit and vegetable harvesting scenarios. Together with the M150 drone, these robots will cover the entire agricultural workflow: tilling, planting, monitoring, managing, and harvesting, all connected and intelligent. Commitment to Empowering Global Farmers Yang concluded his speech with a reaffirmation of StarFront’s mission: “We want to use cutting-edge technology to empower a new generation of farmers, making farming less laborious and food safer.” He called for industry-wide collaboration to drive the precision agriculture revolution, adding that StarFront will continue to invest in R&D, expand its product matrix, and build an open ecosystem. "We stand guard over the fields to secure the harvest of the future," Yang said. "That is our mission and our promise to the society."
- May 28, 2026Medicine & Pharmaceuticals
Alfa Chemistry Advances Biomedical Research with High-Performance Polymer Microspheres
Alfa Chemistry announced the expansion of its advanced polymer microspheres portfolio through its Colloidal Materials Division to support biomedical research involving drug delivery, regenerative medicine, tissue engineering, diagnostics, and functional biomaterials development. Polymer microspheres are increasingly utilized in biomedical systems because their particle morphology, degradation behavior, surface chemistry, and encapsulation performance can be engineered for specific therapeutic and analytical requirements. In controlled-release formulations, microsphere-based carriers can reduce burst release, improve localized retention, and prolong therapeutic exposure of bioactive compounds including peptides, biologics, hydrophobic drugs, and growth factors. Among biodegradable carrier systems, poly(L-lactic acid) (PLLA) microspheres are widely studied for scaffold engineering and sustained-release applications due to their favorable balance between mechanical stability and hydrolytic degradability. Compared with several fast-degrading polyester systems, PLLA exhibits slower degradation kinetics, enabling prolonged structural support and extended release behavior in biomedical formulations. PLLA microspheres are frequently incorporated into porous scaffold systems designed to support cell adhesion, extracellular matrix formation, and tissue regeneration. Their degradation profile also enables temporal control of therapeutic release in long-term delivery systems investigated for peptides, anti-inflammatory compounds, and regenerative therapeutics. Another important biodegradable delivery platform is polycaprolactone (PCL) microspheres , which are recognized for their semicrystalline structure, high drug permeability, and exceptionally slow hydrolysis rate. Due to their prolonged degradation behavior, PCL-based microspheres are increasingly evaluated for long-acting injectable formulations, implantable delivery systems, and regenerative medicine applications requiring extended therapeutic release. PCL microspheres are also being investigated in hybrid biomaterial systems where scaffold stability and controlled growth factor release are required over extended periods. Their slower degradation kinetics can help maintain construct integrity during long-term regenerative processes. In addition to biodegradable biomaterials, non-biodegradable microspheres remain important in analytical and diagnostic technologies. Poly(methyl methacrylate) (PMMA) microspheres are valued for their optical transparency, chemical stability, mechanical robustness, and controlled particle uniformity. These characteristics support applications involving immunodiagnostics, calibration standards, bioseparation systems, imaging technologies, and microfluidic analytical platforms. PMMA microspheres are also utilized as functional substrates for ligand immobilization and surface engineering in biosensing workflows due to their tunable surface chemistry. “Material reproducibility, degradation control, and particle uniformity are becoming increasingly important in advanced biomedical systems,” said a technical representative from Alfa Chemistry. “Polymer microspheres with tunable physicochemical properties can support more precise therapeutic delivery, scaffold engineering, and analytical performance across a wide range of biomedical applications.” With nearly two decades of experience in colloidal materials development, Alfa Chemistry’s Colloidal Materials Division provides standard and customized microsphere solutions, as well as custom development and characterization services, for biomedical and advanced material research applications. About Alfa Chemistry Alfa Chemistry is a global CRO specializing in organic chemistry, material chemistry, medicinal chemistry, and advanced materials. Through its Colloidal Materials Division, the company develops and supplies innovative colloidal materials for applications in biomedicine, diagnostics, catalysis, energy systems, and functional materials research.
SELECT NEWS
SUBSCRIBE TO MARKETERSMEDIA NEWS
Google
News
RSS Feed
ALL NEWS
- French Optical Fashion, Inc. expands Lindberg frames gallery in Manhattan
- Dear Klairs Expands Its US Presence Through OLIVE YOUNG Store Entry Promotion
- Absolute Water Compliance Provides New Legionella Risk Assessment Services In Yorkshire
- Coastal Marine Group introduces local dock builder solutions for complex shorelines
- Dual Restoration highlights Brooklyn training milestone in water damage and restoration
- The Boxery announces expanded paper rolls options for ecommerce shippers
- Prime Window Cleaning combines service estimates for clearer window cleaning pricing
- China and Malaysia jointly deepen vocational education and work together to jointly build a base
- SEO Wires Launches AI Engine That Lets Agencies and Freelancers Deliver Ranking-Ready Articles in Minutes
- AULONG Selected as One of the First Projects in Animoca Brands’ Minds Ecosystem Fund of Up to $10 Million, Launching AI Agent Ecosystem Integration
- Seattle Black Car Service Elevates Executive Transportation Across Seattle and the Pacific Northwest
- Seva Foundation Receives 2026 Global Recognition Award
- Hyperscayle Releases New Framework on AI Agents and RevOps for B2B Sales Operations Teams
- MELBOURNE DANCER, CHOREOGRAPHER, AND EDUCATOR LISA ANTOINETTE HERBERT ANNOUNCES ENTRY INTO THE UNITED STATES ENTERTAINMENT INDUSTRY
- Frost & Sullivan, in Collaboration with ShiJing Medical, Published the 2026 Blue Book on the Current Status and Future Trends of Myopia Management in Children and Adolescent
- Bronx Personal Injury Law Firm Stillman & Stillman Now Serving Castle Hill Residents with Full-Service Legal Representation
- Persefoni Yacht Returns to Monaco Grand Prix for the Fifth Consecutive Year
- Dr. Haunani ‘Iao Honored With The “Excellence In Healthcare Award” At Health 2.0 Conference, Spring Edition
ON INSIDER
- Seva Foundation Receives 2026 Global Recognition Award
- Hyperscayle Releases New Framework on AI Agents and RevOps for B2B Sales Operations Teams
- Bronx Personal Injury Law Firm Stillman & Stillman Now Serving Castle Hill Residents with Full-Service Legal Representation
- On The Move Moving & Junk Removal Expands Professional Moving Services Across Durham Region and the GTA
- Sciotex Helps Manufacturers Modernize Inspection and Automation with AI-Enabled Edge Systems
- Jetpac Helps Fans Avoid Roaming Bill Shock During FIFA 2026
- ISG Provider Lens Study Features Marlabs for Life Sciences Digital Services 2026
- After $176M TRUBAR Exit, Serial Founder Brad Pyatt Launches IQ Pouch to Disrupt the Energy Category
- Srikanth Kavuri Receives a 2026 Global Recognition Award for AI-Driven Software Quality Engineering and Healthcare Infrastructure Modernization
- TechResources.ai names Mike Farrell as President to scale expansion & growth